PDF(Pubmed)
Abstract：
UNASSIGNED: Uveitis, a notable cause of severe visual impairment, is frequently characterized as infectious or noninfectious autoimmune uveitis (AU), the latter of which is commonly associated with younger individuals and systemic diseases. Despite the condition\'s widespread impact, there are substantial gaps in the comprehension of its pathogenesis, clinical presentation, and therapeutic response, particularly concerning systemic disease-associated uveitis.
UNASSIGNED: The current study aims to bridge these gaps through an extensive examination of demographic and clinical features in AU patients, thereby informing future research, and therapeutic strategies, and improving patient outcomes.
UNASSIGNED: This retrospective observational study analyzed 261 patients with systemic disease-associated uveitis from January 2018 to December 2022 in Damascus, Syria. With diagnoses made using the Standardization of Uveitis Nomenclature Working Group Criteria, the study evaluated tailored treatment efficacy at the 24-month post-treatment mark, alongside comprehensive ophthalmic examinations, laboratory evaluations, and radiographic assessments.
UNASSIGNED: In our study, included 87 patients with Systemic Disease-Associated Autoimmune Uveitis (SDA-AU). Women represented 64.36% of this group, and the mean age at diagnosis was 39.8±17.9 years (range 7-71) for men and 43.8±15.4 years (range 11-69). The most reported symptom was a painful red eye (52.87%). The onset of symptoms was sudden for 32.18% of patients, while 67.81% reported gradual development. Complications occurred in 33.33% of patients, including cataracts (41.37% of those with complications) and glaucoma (17.24%). Laboratory evaluations showed elevated inflammation markers in 66.66% of patients. Upon the 24-month assessment, 48.27% of patients achieved complete remission, 37.93% showed significant improvement, while disease worsened in 13.79% of cases.
UNASSIGNED: Our findings demonstrated that the presentation of AU in this cohort frequently precedes the diagnosis of systemic diseases, affirming the vital role of an early and accurate diagnosis of uveitis for the detection of underlying systemic conditions. In conclusion, our study underlines the significance of a comprehensive and multidisciplinary approach in the management of SD-AU, leading to improved prognosis and quality of life for patients.
UNASSIGNED: The current study aims to bridge these gaps through an extensive examination of demographic and clinical features in AU patients, thereby informing future research, and therapeutic strategies, and improving patient outcomes.
UNASSIGNED: This retrospective observational study analyzed 261 patients with systemic disease-associated uveitis from January 2018 to December 2022 in Damascus, Syria. With diagnoses made using the Standardization of Uveitis Nomenclature Working Group Criteria, the study evaluated tailored treatment efficacy at the 24-month post-treatment mark, alongside comprehensive ophthalmic examinations, laboratory evaluations, and radiographic assessments.
UNASSIGNED: In our study, included 87 patients with Systemic Disease-Associated Autoimmune Uveitis (SDA-AU). Women represented 64.36% of this group, and the mean age at diagnosis was 39.8±17.9 years (range 7-71) for men and 43.8±15.4 years (range 11-69). The most reported symptom was a painful red eye (52.87%). The onset of symptoms was sudden for 32.18% of patients, while 67.81% reported gradual development. Complications occurred in 33.33% of patients, including cataracts (41.37% of those with complications) and glaucoma (17.24%). Laboratory evaluations showed elevated inflammation markers in 66.66% of patients. Upon the 24-month assessment, 48.27% of patients achieved complete remission, 37.93% showed significant improvement, while disease worsened in 13.79% of cases.
UNASSIGNED: Our findings demonstrated that the presentation of AU in this cohort frequently precedes the diagnosis of systemic diseases, affirming the vital role of an early and accurate diagnosis of uveitis for the detection of underlying systemic conditions. In conclusion, our study underlines the significance of a comprehensive and multidisciplinary approach in the management of SD-AU, leading to improved prognosis and quality of life for patients.
摘要：
■葡萄膜炎，严重视力障碍的显著原因，常表现为感染性或非感染性自身免疫性葡萄膜炎（AU），后者通常与年轻个体和全身性疾病有关。尽管条件的广泛影响，对其发病机制的理解存在很大差距，临床表现,和治疗反应，特别是关于全身性疾病相关葡萄膜炎。
■本研究旨在通过广泛检查AU患者的人口统计学和临床特征来弥合这些差距。从而为未来的研究提供信息，和治疗策略，改善患者预后。
■这项回顾性观察性研究分析了2018年1月至2022年12月在大马士革的261例系统性疾病相关葡萄膜炎患者，叙利亚。使用葡萄膜炎命名标准化工作组标准进行诊断，该研究在治疗后24个月评估了定制的治疗效果，除了全面的眼科检查，实验室评估,和射线照相评估。
■在我们的研究中，纳入87例系统性疾病相关自身免疫性葡萄膜炎(SDA-AU)患者。妇女占这一群体的64.36%，男性的诊断平均年龄为39.8±17.9岁（范围7-71岁），男性为43.8±15.4岁（范围11-69岁）。报告最多的症状是疼痛的红眼（52.87％）。32.18%的患者出现症状突然,而67.81%的人报告说是逐步发展的。33.33%的患者出现并发症,包括白内障（占并发症的41.37％）和青光眼（17.24％）。实验室评估显示66.66％的患者炎症标志物升高。经过24个月的评估，48.27%的患者达到完全缓解,37.93%表现出显著改善，而13.79%的病例病情恶化。
■我们的研究结果表明，AU在该队列中的出现通常先于全身性疾病的诊断，确认葡萄膜炎的早期和准确诊断对于检测潜在的全身状况的重要作用。总之,我们的研究强调了综合和多学科方法在SD-AU管理中的重要性，改善患者的预后和生活质量。
■本研究旨在通过广泛检查AU患者的人口统计学和临床特征来弥合这些差距。从而为未来的研究提供信息，和治疗策略，改善患者预后。
■这项回顾性观察性研究分析了2018年1月至2022年12月在大马士革的261例系统性疾病相关葡萄膜炎患者，叙利亚。使用葡萄膜炎命名标准化工作组标准进行诊断，该研究在治疗后24个月评估了定制的治疗效果，除了全面的眼科检查，实验室评估,和射线照相评估。
■在我们的研究中，纳入87例系统性疾病相关自身免疫性葡萄膜炎(SDA-AU)患者。妇女占这一群体的64.36%，男性的诊断平均年龄为39.8±17.9岁（范围7-71岁），男性为43.8±15.4岁（范围11-69岁）。报告最多的症状是疼痛的红眼（52.87％）。32.18%的患者出现症状突然,而67.81%的人报告说是逐步发展的。33.33%的患者出现并发症,包括白内障（占并发症的41.37％）和青光眼（17.24％）。实验室评估显示66.66％的患者炎症标志物升高。经过24个月的评估，48.27%的患者达到完全缓解,37.93%表现出显著改善，而13.79%的病例病情恶化。
■我们的研究结果表明，AU在该队列中的出现通常先于全身性疾病的诊断，确认葡萄膜炎的早期和准确诊断对于检测潜在的全身状况的重要作用。总之,我们的研究强调了综合和多学科方法在SD-AU管理中的重要性，改善患者的预后和生活质量。
